OGEN
Oragenics, Inc.
There isn't enough reported data to score OGEN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
OGEN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
OGEN's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OGEN PE Valuation
OGEN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OGEN Forward outlook
There aren't enough analyst estimates for OGEN to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$24.05 | +$185.95 |
| Q2 2025 | -$33.49 | +$190.61 |
| Q1 2025 | -$45.69 | +$208.41 |
| Q4 2024 | -$63.09 | +$212.31 |
| Q3 2024 | -$210.00 | -$63.49 |
| Q2 2024 | -$224.10 | -$49.09 |
| Q1 2024 | -$254.10 | -$70.39 |
| Q4 2023 | -$275.40 | -$61.99 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 111% for OGEN versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
OGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $7.5K | -91% |
| Q2 2023 | $13.2K | -57% |
| Q1 2023 | $17K | +13% |
OGEN's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -28053% | -23514 points |
| Q2 2023 | -23622% | -11763 points |
| Q1 2023 | -17063% | +13502 points |
| Q3 2022 | -4539% | N/A |
| Q2 2022 | -11859% | N/A |
| Q1 2022 | -30565% | N/A |
OGEN's operating margin was −28053% last quarter, down 16194 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
OGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | +$951.1K |
| Q2 2026 | -$2.2M | -$872.4K |
| Q1 2026 | -$2.2M | -$88.6K |
| Q4 2025 | -$2.8M | -$817.1K |
| Q3 2025 | -$3M | -$1M |
| Q2 2025 | -$1.3M | +$230.2K |
| Q1 2025 | -$2.1M | +$952.2K |
| Q4 2022 | -$2.4M | -$532.1K |
OGEN has burned cash in almost every quarter: −$9M over the past year, against −$8M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over OGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
OGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +83.4K shares |
| 1 year | +517% | +3.8M shares |
| 3 years | +6585% | +4.4M shares |
| 5 years | +7787% | +4.5M shares |
| Available history | +19107% | +4.5M shares |
OGEN has 5M diluted shares, up 517% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over OGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
OGEN Net Leverage
OGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
OGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 5.7 | Oversold |
OGEN's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
OGEN PE vs Healthcare Sector
OGEN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
OGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.42 | 17% below |
| 20 week MA | $0.48 | 27% below |
| 50 week MA | $0.63 | 44% below |
| 100 week MA | $2.60 | 87% below |
| 200 week MA | $41.7 | 99% below |
OGEN is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over OGEN on trend strength, trading above more of its moving averages.
OGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $948.6 | $774.0 | -18% |
| 2021 | $774.0 | $867.8 | +12% |
| 2022 | $867.8 | $261.0 | -70% |
| 2023 | $261.0 | $168.9 | -35% |
| 2024 | $168.9 | $13.6 | -92% |
| 2025 | $13.6 | $0.86 | -94% |
| 2026 YTD | $0.86 | $0.35 | -59% |
OGEN has finished four years in a row lower, and it's down 59% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over OGEN on returns for 2026, with the stronger performance.